Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
New gene therapy study findings have been published by scientists at Duke University, Human Vaccine Institute
December 31st, 2008
New research, 'Comparison of multiple vaccine vectors in a single heterologous prime-boost trial,' is the subject of a report. According to recent research from the United States, "The prevention of infectious disease via prophylactic immunization is a mainstay of global public health efforts. Vaccine design would be facilitated by a better understanding of the type and durability of immune responses generated by different vaccine vectors." "We report here the results of a comparative immunogenicity trial of six different vaccine vectors expressing the same insert antigen, cowpox virus B5 (CPXV-B5). Of those vectors tested, recombinant adenovirus (rAd5) was the most...
Source: Vaccine Weekly (2008-12-31)
|
